Biondo Investment Advisors LLC Sells 1,625 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Biondo Investment Advisors LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 3.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 53,450 shares of the company’s stock after selling 1,625 shares during the period. Biondo Investment Advisors LLC’s holdings in TransMedics Group were worth $3,333,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TMDX. Clear Creek Financial Management LLC purchased a new stake in shares of TransMedics Group in the 4th quarter worth about $352,000. Vaughan Nelson Investment Management L.P. raised its stake in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after buying an additional 32,605 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after buying an additional 34,947 shares during the period. State of Michigan Retirement System bought a new stake in TransMedics Group during the 4th quarter valued at approximately $6,734,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Oppenheimer reissued an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Down 2.6 %

NASDAQ:TMDX opened at $68.58 on Friday. The firm has a 50-day simple moving average of $69.11 and a two-hundred day simple moving average of $88.41. The firm has a market cap of $2.31 billion, a P/E ratio of 72.96 and a beta of 2.12. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.